Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients

Turkish Journal of Gastroenterology - Turkey
doi 10.5152/tjg.2016.160000
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AVES Publishing Co.

Related search

Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV Genotype: FDA's Evaluation

Hepatology
MedicineHepatology
2018English

Sofosbuvir, a Significant Paradigm Change in HCV Treatment

Journal of Clinical and Translational Hepatology
2015English

Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia

American Journal of Hematology
Hematology
2018English

Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients After Treatment With Sofosbuvir and Daclatasvir

International Journal of Current Microbiology and Applied Sciences
2018English

Ledipasvir and Sofosbuvir for HCV-infection in Patients Coinfected With HBV

Antiviral Therapy
Infectious DiseasesPharmacology
2016English

SVR12 Rates Higher Than 99% After Sofosbuvir/Velpatasvir Combination in HCV Infected Patients With F0-F1 Fibrosis Stage: A Real World Experience

PLoS ONE
Multidisciplinary
2019English

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy